Literature DB >> 23536579

HBxAPα/Rsf-1-mediated HBx-hBubR1 interactions regulate the mitotic spindle checkpoint and chromosome instability.

Sunyoung Chae1, Jae-Hoon Ji, Soon-Hwan Kwon, Ho-Soo Lee, Jung Mi Lim, Dongmin Kang, Chang-Woo Lee, Hyeseong Cho.   

Abstract

Hepatitis B virus (HBV) X protein (HBx), encoded by the HBV genome, is involved in the development of HBV-mediated liver cancer, whose frequency is highly correlated with chromosomal instability (CIN). We reported previously that HBx induces mitotic checkpoint dysfunction by targeting the human serine/threonine kinase BubR1 (hBubR1). However, the underlying mechanism remained unresolved. Here, we show that HBx protein-associated protein α (HBxAPα)/Rsf-1 associates with hBubR1 and HBx in the chromatin fraction during mitosis. Depletion of HBxAPα/Rsf-1 abolished the interaction between HBx and hBubR1, indicating that HBxAPα/Rsf-1 mediates these interactions. Knockdown of HBxAPα/Rsf-1 with small interfering RNA did not affect the recruitment of hBubR1 to kinetochores; however, it did significantly impair HBx targeting to kinetochores. A deletion mutant analysis revealed that two Kunitz domains of HBx, the Cdc20-binding domain of hBubR1 and full-length of HBxAPα/Rsf-1 were essential for these interactions. Thus, binding of HBx to hBubR1, stabilized by HBxAPα/Rsf-1, significantly attenuated hBubR1 binding to Cdc20 and consequently increased the rate of mitotic aberrations. Collectively, our data show that the HBx impairs hBubR1 function and induces CIN through HBxAPα/Rsf-1, providing a novel mechanism for induction of genomic instability by a viral pathogen in hepatocarcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23536579     DOI: 10.1093/carcin/bgt105

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  8 in total

1.  Host transcription factor Speckled 110 kDa (Sp110), a nuclear body protein, is hijacked by hepatitis B virus protein X for viral persistence.

Authors:  Isha Sengupta; Dipanwita Das; Shivaram Prasad Singh; Runu Chakravarty; Chandrima Das
Journal:  J Biol Chem       Date:  2017-10-18       Impact factor: 5.157

2.  The HBx oncoprotein of hepatitis B virus deregulates the cell cycle by promoting the intracellular accumulation and re-compartmentalization of the cellular deubiquitinase USP37.

Authors:  Nehul Saxena; Vijay Kumar
Journal:  PLoS One       Date:  2014-10-27       Impact factor: 3.240

3.  Rsf‑1 regulates malignant melanoma cell viability and chemoresistance via NF‑κB/Bcl‑2 signaling.

Authors:  Jiani He; Lin Fu; Qingchang Li
Journal:  Mol Med Rep       Date:  2019-08-23       Impact factor: 2.952

4.  The Effects and Underlying Mechanisms of Hepatitis B Virus X Gene Mutants on the Development of Hepatocellular Carcinoma.

Authors:  Rui Pu; Wenbin Liu; Xinyu Zhou; Xi Chen; Xiaomei Hou; Shiliang Cai; Liping Chen; Jianfeng Wu; Fan Yang; Xiaojie Tan; Jianhua Yin; Xin Wang; Guangwen Cao
Journal:  Front Oncol       Date:  2022-02-10       Impact factor: 6.244

Review 5.  RSF1 in cancer: interactions and functions.

Authors:  Guiyang Cai; Qing Yang; Wei Sun
Journal:  Cancer Cell Int       Date:  2021-06-19       Impact factor: 5.722

6.  The chromatin remodeller RSF1 is essential for PLK1 deposition and function at mitotic kinetochores.

Authors:  Ho-Soo Lee; Yong-Yea Park; Mi-Young Cho; Sunyoung Chae; Young-Suk Yoo; Myung-Hee Kwon; Chang-Woo Lee; Hyeseong Cho
Journal:  Nat Commun       Date:  2015-08-10       Impact factor: 14.919

7.  The chromatin remodeler RSF1 controls centromeric histone modifications to coordinate chromosome segregation.

Authors:  Ho-Soo Lee; Zhonghui Lin; Sunyoung Chae; Young-Suk Yoo; Byung-Gyu Kim; Youngsoo Lee; Jared L Johnson; You-Sun Kim; Lewis C Cantley; Chang-Woo Lee; Hongtao Yu; Hyeseong Cho
Journal:  Nat Commun       Date:  2018-09-21       Impact factor: 14.919

8.  Identification of potential key genes and pathways in hepatitis B virus-associated hepatocellular carcinoma by bioinformatics analyses.

Authors:  Xiang Zhang; Lingchen Wang; Yehong Yan
Journal:  Oncol Lett       Date:  2020-03-20       Impact factor: 2.967

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.